These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2265474)

  • 1. H-ras activation and ras p21 expression in bladder tumors induced in F344/NCr rats by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Enomoto T; Ward JM; Perantoni AO
    Carcinogenesis; 1990 Dec; 11(12):2233-8. PubMed ID: 2265474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of H-ras oncogene in rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Fujita J; Ohuchi N; Ito N; Reynolds SH; Yoshida O; Nakayama H; Kitamura Y
    J Natl Cancer Inst; 1988 Mar; 80(1):37-43. PubMed ID: 3276902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of ras oncogene activation in rat urinary bladder carcinomas induced by N-methyl-N-nitrosourea or N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Masui T; Mann AM; Macatee TL; Okamura T; Garland EM; Smith RA; Cohen SM
    Carcinogenesis; 1992 Dec; 13(12):2281-5. PubMed ID: 1473235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating missense mutations in Ha-ras-1 genes in a malignant subset of bladder lesions induced by N-butyl-N-(4-hydroxybutyl)nitrosamine or N-[4-(5-nitro-2-furanyl)-2-thiazolyl]formamide.
    Jones RF; Debiec-Rychter M; Zukowski K; Wang CY
    Mol Carcinog; 1990; 3(6):393-402. PubMed ID: 2278634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.
    Ota T; Asamoto M; Toriyama-Baba H; Yamamoto F; Matsuoka Y; Ochiya T; Sekiya T; Terada M; Akaza H; Tsuda H
    Carcinogenesis; 2000 Jul; 21(7):1391-6. PubMed ID: 10874018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation adduct formation and H-ras gene mutations in progression of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tumors caused by a single exposure to N-methyl-N-nitrosourea.
    Shibata MA; Shirai T; Ogawa K; Takahashi S; Wild CP; Montesano R; Tsuda H; Ito N
    Carcinogenesis; 1994 Dec; 15(12):2965-8. PubMed ID: 8001265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts.
    Masui T; Mann AM; Macatee TL; Okamura T; Garland EM; Fujii H; Pelling JC; Cohen SM
    Cancer Res; 1991 Jul; 51(13):3471-5. PubMed ID: 2054786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutation in codons 12 and 61 of the Ha-ras gene in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
    Masui T; Mann AM; Garland EM; Okamura T; Johansson PL; Cohen SM
    Mol Carcinog; 1990; 3(4):210-5. PubMed ID: 2206284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Masui T; Don I; Takada N; Ogawa K; Shirai T; Fukushima S
    Carcinogenesis; 1994 Oct; 15(10):2379-81. PubMed ID: 7955081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
    Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
    Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity in (LewisxF344)F1 rat urinary bladder tumors induced with N-butyl-N-(4-hydroxybutyl)nitrosamine followed by dimethylarsinic acid or sodium L-ascorbate.
    Chen T; Na Y; Wanibuchi H; Yamamoto S; Lee CC; Fukushima S
    Jpn J Cancer Res; 1999 Aug; 90(8):818-23. PubMed ID: 10543252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine.
    Masui T; Dong Y; Yamamoto S; Takada N; Nakanishi H; Inada K; Fukushima S; Tatematsu M
    Cancer Lett; 1996 Jul; 105(1):105-12. PubMed ID: 8689624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
    Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Harvey ras oncogene point mutations and their expression in methylbenzylnitrosamine-induced esophageal tumorigenesis.
    Barch DH; Jacoby RF; Brasitus TA; Radosevich JA; Carney WP; Iannaccone PM
    Carcinogenesis; 1991 Dec; 12(12):2373-7. PubMed ID: 1747941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing analysis of Ha-, Ki-, and N-ras genes in rat urinary bladder tumors induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) and sodium saccharin.
    Masui T; Mann AM; Borgeson CD; Garland EM; Okamura T; Fujii H; Pelling JC; Cohen SM
    Teratog Carcinog Mutagen; 1993; 13(5):225-33. PubMed ID: 7905676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and H-ras mutations and microsatellite instability in renal pelvic carcinomas of NON / Shi mice treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine: different genetic alteration from urinary bladder carcinoma.
    Gen H; Yamamoto S; Morimura K; Min W; Mitsuhashi M; Murai T; Mori S; Hosono M; Oohara T; Makino S; Wanibuchi H; Fukushima S
    Jpn J Cancer Res; 2001 Dec; 92(12):1278-83. PubMed ID: 11749692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats.
    Watatani M; Perantoni AO; Reed CD; Enomoto T; Wenk ML; Rice JM
    Cancer Res; 1989 Mar; 49(5):1103-9. PubMed ID: 2645046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct DNA sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide or N-methyl-N-nitrosourea.
    Masui T; Mann AM; Macatee TL; Garland EM; Okamura T; Smith RA; Cohen SM
    Carcinogenesis; 1991 Oct; 12(10):1975-8. PubMed ID: 1682063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of involvement of p53 gene mutations in N-methyl-N-nitrosourea-induced bladder tumor progression in N-butyl-N-(4-hydroxybutyl)nitrosamine-treated rats and no suppression by indomethacin.
    Ozaki M; Shibata MA; Takahashi S; Orita SI; Kawabe M; Shirai T
    Cancer Lett; 1997 May; 115(2):249-55. PubMed ID: 9149132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H-ras p21 and peanut lectin immunoreactivity of hyperplastic, preneoplastic and neoplastic urinary bladder lesions in rats.
    Ward JM; Hagiwara A; Tsuda H; Tatematsu M; Ito N
    Jpn J Cancer Res; 1988 Feb; 79(2):152-5. PubMed ID: 3130347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.